Gabriela Andrade Vasques

Gabriela Andrade Vasques

Auto-generated profile, based on publicly available information

Gabriela Andrade Vasques

Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM/25, Disciplina de Endocrinologia, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
GVGabriela A. Vasques
Gabriela A. Vasques
NANaoko Amano
Naoko Amano
ADAna J. Docko
Ana J. Docko
MFMariana F. A. Funari
Mariana F. A. Funari
EQElisangela P. S. Quedas
Elisangela P. S. Quedas
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Based on the stature observed in relatives of patients with acromesomelic dysplasia, type Maroteaux, homozygous for mutations in natriuretic peptide receptor B gene (NPR2), it has been suggested that heterozygous mutations in this gene could be responsible for the growth impairment observed in some children with idiopathic short stature (ISS). The objective of the study was to investigate the presence of NPR2 mutations in a group of patients with ISS. The NPR2 coding region was directly sequenced in 47 independent patients with ISS. The functional consequences of NPR2 nonsynonymous variations were established using in vitro cell-based assays. Three novel heterozygous NPR2 mutations were identified: c.226T>C (p.Ser76Pro), c.788G>C (p.Arg263Pro), and c.2455C>T (p.Arg819Cys). These allelic variants were not found in our controls or in the 1000 Genomes database. In silico analysis suggested that the three missense mutations are probably damaging. All of them were selected for in vitro functional evaluation. Cells transfected with the three mutants failed to produce cyclic GMP after treatment with C-type natriuretic peptide. Cells cotransfected with mutant and wild-type-NPR-B (1:1) showed a significant decrease in cGMP levels after C-type natriuretic peptide stimulation in comparison with cells cotrasnfected with empty vector and wild type, suggesting a dominant-negative effect. These three mutations segregated with short stature phenotype in an autosomal dominant pattern (height SD score ranged from -4.5 to -1.7). One of these patients and two relatives have disproportionate short stature, whereas in another patient a nonspecific skeletal abnormality was observed. All three of these patients were treated with recombinant human GH (33-50 μg/kg · d) without significant height SD score change during therapy. We identified heterozygous NPR2 mutations in 6% of patients initially classified as ISS. Affected patients have mild and variable degrees of short stature without a distinct phenotype. Heterozygous mutations in NPR2 could be an important cause of nonsyndromic familial short stature.

15 November 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
GVGabriela A Vasques
Gabriela A Vasques
MFMariana F A Funari
Mariana F A Funari
FFFrederico M Ferreira
Frederico M Ferreira
MAMiriam Aza-Carmona
Miriam Aza-Carmona
LSLucia Sentchordi-Montané
Lucia Sentchordi-Montané
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Context Genetic evaluation has been recognized as an important tool to elucidate the causes of growth disorders. Objective To investigate the etiology of short stature and to determine the phenotype of patients with IHH mutations, including the response to growth hormone (rhGH) therapy. Patients and Methods We studied 17 families with autosomal dominant short stature using whole exome sequencing and screened IHH defects in 290 patients with growth disorders. Molecular analyses were performed to evaluate the potential impact of N-terminal IHH variants. Results We identified 10 pathogenic or possibly pathogenic variants in IHH, an important regulator of endochondral ossification. Molecular analyses revealed a smaller potential energy of mutated IHH molecules. The allele frequency of rare predicted to be deleterious IHH variants found in short stature samples (1.6%) was higher than that observed in two control cohorts (0.017% and 0.08%; p<0.001). Identified IHH variants segregate with short stature in a dominant inheritance pattern. Affected individuals typically manifest mild disproportional short stature with a frequent finding of shortening of the middle phalanx of the 5th finger. None of them have classical features of brachydactyly type A1, which was previously associated with IHH mutations. Five patients heterozygous for IHH variants had a good -response to rhGH therapy: mean height SDS change in one year of 0.6. Conclusion Our study demonstrated the association of pathogenic variants in IHH with short stature with non-specific skeletal abnormalities and established a novel and frequent cause of growth disorder, with a preliminary good response to rhGH.

3 September 2014 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
PDF file
GVGabriela A. Vasques
Gabriela A. Vasques
IAIvo J.P. Arnhold
Ivo J.P. Arnhold
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
The C-type natriuretic peptide (CNP) and its receptor (NPR-B) are recognized as important regulators of longitudinal growth. Animal models involving CNP or NPR-B genes (Nppc or Npr2) support the fundamental role of CNP/NPR-B for endochondral ossification. Studies with these animals allow the development of potential drug therapies for dwarfism. Polymorphisms in two genes related to the CNP pathway have been implicated in height variability in healthy individuals. Biallelic loss-of-function mutations in NPR-B gene (NPR2) cause acromesomelic dysplasia type Maroteux, a skeletal dysplasia with extremely short stature. Heterozygous mutations in NPR2 are responsible for nonsyndromic familial short stature. Conversely, heterozygous gain-of-function mutations in NPR2 cause tall stature, with a variable phenotype. A phase 2 multicenter and multinational trial is being developed to evaluate a CNP analog treatment for achondroplasia. Pediatricians and endocrinologists must be aware of growth disorders related to natriuretic peptides, although there is still much to be learned about its diagnostic and therapeutic use.

1 February 2019 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
GVGabriela A. Vasques
Gabriela A. Vasques
NANathalia L. M. Andrade
Nathalia L. M. Andrade
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
Short stature is a common feature, and frequently remains without a specific diagnosis after conventional clinical and laboratorial evaluation. Longitudinal growth is mainly determined by genetic factors, and hundreds of common variants have been associated to height variability among healthy individuals. Although isolated short stature may be caused by the combination of variants, with a deleterious impact on the growth of individuals with polygenic inheritance, recent studies have pointed out some monogenic defects as the cause of the growth disorder observed in nonsyndromic children. The majority of these defects are in genes related to the growth plate cartilage and in the growth hormone (GH) – insulin-like growth factor 1 (IGF-1) axis. Affected patients usually present the mildest spectrum of some forms of skeletal dysplasia, or subtle abnormalities of laboratory tests, suggesting hormonal resistance or insensibility. The lack of specific characteristics, however, does not allow formulation of a definitive diagnosis without the use of broad genetic studies. Thus, molecular genetic studies including panels of genes or exome analysis will become essential in investigating and identifying the causes of isolated short stature in children, with a crucial impact on treatment and follow-up.

1 January 2019 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
GVGabriela A. Vasques
Gabriela A. Vasques
NANathalia L. M. Andrade
Nathalia L. M. Andrade
FCFernanda A. Correa
Fernanda A. Correa
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
The somatotropic axis is the main hormonal regulator of growth. Growth hormone (GH), also known as somatotropin, and insulin-like growth factor 1 (IGF-1) are the key components of the somatotropic axis. This axis has been studied for a long time and the knowledge of how some molecules could promote or impair hormones production and action has been growing over the last decade. The enhancement of large-scale sequencing techniques has expanded the spectrum of known genes and several other candidate genes that could affect the GH-IGF1-bone pathway. To date, defects in more than forty genes were associated with an impairment of the somatotropic axis. These defects can affect from the secretion of GH to the bioavailability and action of IGF-1. Affected patients present a large heterogeneous group of conditions associated with growth retardation. In this review, we focus on the description of the GH-IGF axis genetic defects reported in the last decade. Arch Endocrinol Metab. 2019;63(6):608-17.

15 November 2019 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
PBPriscila Sales Barroso
Priscila Sales Barroso
AJAlexander Augusto Lima Jorge
Alexander Augusto Lima Jorge
ALAntonio Marcondes Lerario
Antonio Marcondes Lerario
LMLuciana Ribeiro Montenegro
Luciana Ribeiro Montenegro
GVGabriela Andrade Vasques
Gabriela Andrade Vasques
ALAna Claudia Latronico
Ana Claudia Latronico
Introduction: Constitutional delay of growth and puberty (CDGP) is the most prevalent cause of delayed puberty in both sexes. Family history of delayed puberty (2 or more affected members in a family) has been evidenced in 50–75% of patients with CDGP and the inheritance is often consistent with autosomal dominant pattern, with or without complete penetrance. However, the molecular basis of CDGP is not completely understood. Objective: To characterize the clinical and genetic features of a CDGP cohort. Methods: Fifty-nine patients with CDGP (48 boys and 11 girls) underwent careful and long-term clinical evaluation. Genetic analysis was performed using a custom DNA target enrichment panel designed to capture 36 known and candidate genes implicated with pubertal development. Results: All patients had spontaneous or induced pubertal development (transient hormonal therapy) prior to 18 years of age. The mean clinical follow-up time was 46 ± 28 months. Male predominance (81%), short stature (91%), and family history of delayed puberty (59%) were the main clinical features of this CDGP ­cohort. Genetic analyses revealed 15 rare heterozygous missense variants in 15 patients with CDGP (25%) in seven different genes (IGSF10, GHSR, CHD7, SPRY4, WDR11, SEMA3A,and IL17RD). IGSF10 and GHSR were the most prevalent affected genes in this group. Conclusions: Several rare dominant variants in genes implicated with GnRH migration and metabolism were identified in a quarter of the patients with familial or sporadic CDGP, suggesting genetic heterogeneity in this frequent pediatric condition.